返回 
加入收藏
依洛尤单抗与普罗布考对超高危动脉粥样硬化心血管疾病患者PCI术后的临床效果对比
x
请在关注微信后，向客服人员索取文件
| 篇名： | 依洛尤单抗与普罗布考对超高危动脉粥样硬化心血管疾病患者PCI术后的临床效果对比 |
| TITLE： | Comparison of clinical efficacy of evolocumab and probucol after PCI in patients with ultra-high-risk atherosclerotic cardiovascular disease |
| 摘要： | 目的 对比依洛尤单抗与普罗布考在经皮冠状动脉介入治疗（PCI）术后的超高危动脉粥样硬化心血管疾病（ASCVD）患者中的疗效及安全性。方法回顾性纳入2023年1月1日至2024年12月31日我院收治的156例接受PCI的超高危ASCVD患者，根据用药方案将其分为依洛尤单抗组（n＝86）和普罗布考组（n＝70）。比较两组患者治疗前和治疗6个月后血脂相关指标[总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、甘油三酯、脂蛋白a以及血脂达标率]、炎症相关指标[白细胞介素6（IL-6）、C反应蛋白（CRP）]、心功能相关指标（左室射血分数、左室收缩末内径、左室舒张末内径、N末端B型利钠肽原）等的变化。评估两组患者治疗期间急性心肌梗死、支架内再狭窄、急性心力衰竭、脑出血、脑卒中等不良事件的发生情况。结果治疗前，两组患者上述各项指标的差异均无统计学意义（P＞0.05）。治疗6个月后，两组患者的血脂（HDL-C除外）及炎症相关指标均较治疗前显著改善（P＜0.05），且依洛尤单抗组在降低TC、LDL-C、IL-6、CRP及提高血脂达标率方面均优于普罗布考组（P＜0.05）。两组患者治疗前后的心功能相关指标及治疗期间的不良事件发生率差异均无统计学意义（P＞0.05）。结论在接受PCI的超高危ASCVD患者中，上述两种治疗方案均可改善血脂及减少炎症反应，且短期随访期内安全性良好。依洛尤单抗在TC、LDL-C和炎症指标降低幅度及血脂达标率方面优于普罗布考。 |
| ABSTRACT： | OBJECTIVE To compare the efficacy and safety of evolocumab and probucol in patients with ultra-high-risk atherosclerotic cardiovascular disease （ASCVD） following percutaneous coronary intervention （PCI）. METHODS A retrospective analysis was conducted on 156 ultra-high-risk ASCVD patients who underwent PCI in our institution between January 1， 2023 and December 31， 2024. According to the lipid-lowering regimen， the patients were categorized into evolocumab group （ n ＝86） and probucol group （ n ＝70）. Changes in lipid parameters [total cholesterol （TC）， low-density lipoprot ein cholesterol （LDL-C）， high-density lipoprotein cholesterol （HDL-C）， triglycerides， lipoprotein （a）， and lipid goal achievement rate ] ， inflammatory markers [interleukin-6 （IL-6） and C-reactive protein （CRP） ] ， and cardiac function indices （left ventricular ejection fraction， left ventricular end-systolic diameter， left ventricular end-diastolic diameter， and N-terminal pro-B-type natriuretic peptide） were compared between two groups at baseline and after 6 months of treatment. The incidence of adverse clinical events during treatment， including acute myocardial infarction， in-stent restenosis， acute heart failure， cerebral hemorrhage， and stroke， was also evaluated. RESULTS No statistically significant differences were observed between the two groups at baseline （ P ＞0.05）. After 6 months of treatment， both groups demonstrated significant improvements in lipid profiles （except HDL-C） and inflammatory markers compared to those at baseline （ P ＜0.05）. The evolocumab group exhibited greater reductions in TC， LDL-C， IL-6， and CRP， along with a higher lipid target achievement rate， compared with the probucol group （ P ＜0.05）. There were no statistically significant differences in the cardiac function-related indicators before and after treatment between the two groups， nor in the incidence of adverse events during the treatment （ P ＞0.05）. CONCLUSIONS For ultra-high-risk ASCVD patients after PCI， both of the above treatment options are associated with improvements in blood lipid and inflammatory response， with good safety during short-term follow-up. Evolocumab shows superior efficacy in TC， LDL-C and inflammatory markers reduction and lipid target achievement， compared to probucol. |
| 期刊： | 2026年第37卷第05期 |
| 作者： | 袁毅；李娜；孙海英；孙婧；马永强；吴彦；杨国红；刘军翔 |
| AUTHORS： | YUAN Yi，LI Na，SUN Haiying，SUN Jing，MA Yongqiang，WU Yan，YANG Guohong，LIU Junxiang |
| 关键字： | 依洛尤单抗；普罗布考；超高危动脉粥样硬化心血管疾病；经皮冠状动脉介入治疗；疗效；安全性 |
| KEYWORDS： | evolocumab； probucol； ultra-high-risk atherosclerotic cardiovascular disease； percutaneous coronary intervention； |
| 阅读数： | 1 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
